Introduction
COVID-19NAbs
EMERGENCY
Until recently, the unprecedented COVID-19 pandemic had been declared a Public Health Emergency of International Concern by the World Health Organization. Due to the continuous evolution of SARS-CoV-2, its variants led to a high risk of COVID-19 global transmission. Although vaccination has played important roles in preventing and controlling COVID-19NAbs blocking the entry of SARS-CoV-2 into host cells have been developed for the COVID-19 prevention or therapy. Several SARS-CoV-2 targeting monoclonal antibodies (mAbs) have previously been authorized for use through an emergency use authorization (EUA)A8G6 is a combination of 58G6 and 55A8 monoclonal NAbs which were identified from COVID-19 convalescent patients at early 2020Here we conducted an open-label, non-randomized, two-arm, blank-controlled trial among close contacts of COVID-19 patients in several designated quarantine hotels to assessed the effectiveness and safety of A8G6 intranasal spray for the post-exposure prophylaxis of COVID-19 during the Omicron BA.5.2 wave occurred in November, 2022 in Chongqing, China.